Is curing patients a sustainable business model?” Goldman Sachs analysts ask

Analyst report notes that Gilead’s hep C cure will make less than $4 billion this year.





The Goldman Sachs bank logo is seen reflected on the screen of a mobile phone in this photo illustration on November 15, 2017.
Enlarge / The Goldman Sachs bank logo is seen reflected on the screen of a mobile phone in this photo illustration on November 15, 2017.


532 with 258 posters participating, including story author

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.


Analyst Salveen Richter and colleagues laid it out:

The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.

For a real-world example, they pointed to Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.

“[Gilead]’s rapid rise and fall of its hepatitis C franchise highlights one of the dynamics of an effective drug that permanently cures a disease, resulting in a gradual exhaustion of the prevalent pool of patients,” the analysts wrote. The report noted that diseases such as common cancers—where the “incident pool remains stable”—are less risky for business.

To get around the sustainability issue overall, the report suggests that biotech companies focus on diseases or conditions that seem to be becoming more common and/or are already high-incidence. It also suggests that companies be innovative and constantly expanding their portfolio of treatments. This can “offset the declining revenue trajectory of prior assets." Lastly, it hints that, as such cures come to fruition, they could open up more investment opportunities in treatments for “disease of aging.”

Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.

This post has been updated.


Views: 49

Comment

You need to be a member of 12160 Social Network to add comments!

Join 12160 Social Network

Comment by Chris of the family Masters on May 16, 2019 at 7:54pm

This sums it up. Rockefeller's 'medicine' is a fraud.

Comment by Diana on May 16, 2019 at 7:44pm

They actually had to do a report?  It seems pretty obvious that the big money is in drugs that patients have to take for life - steady income stream.  It's even better if other drugs have to be prescribed for side effects from the original drug.

"Destroying the New World Order"

THANK YOU FOR SUPPORTING THE SITE!

mobile page

12160.info/m

12160 Administrators

 

TOP CONTENT THIS WEEK

Latest Activity

Lori and Mrs. Tif Morgan are now friends
14 minutes ago
Central Scrutinizer commented on Central Scrutinizer's photo
Thumbnail

I Want To Believe

"LMAO @ Burbia  :-O"
35 minutes ago
Mrs. Tif Morgan posted discussions
39 minutes ago
Central Scrutinizer posted a photo

Where's Waldo?

Give up???---He's hiding behind the bong on left
41 minutes ago
JoeG favorited Diana's photo
43 minutes ago
JoeG favorited Diana's photo
43 minutes ago
Less Prone favorited Doc Vega's blog post Wondering
1 hour ago
Less Prone favorited Boris's page Tulsi Shitting on Hillary
1 hour ago
Central Scrutinizer added a discussion to the group Marijuana- "Its not just for getting stoned anymore"
Thumbnail

Yes Virginia, There is a Sativa Clause

Weed Dealing ain't quite what it used to be anymore, looks like my Co-Knek-shun has stepped up…See More
1 hour ago
Less Prone favorited Central Scrutinizer's blog post Clinton Takes Veiled Shot at Gabbard: ‘She’s the Favorite of the Russians’ to Run Third-Party
1 hour ago
Less Prone favorited Diana's photo
1 hour ago
Boris commented on Boris's page Remember the young Chinese-American woman who was stripped of her Miss Michigan beauty pageant title for her pro trump tweets? Turns out she has more American Indian in her than Elizabeth Warren.
"True"
1 hour ago
Boris commented on Central Scrutinizer's blog post Clinton Takes Veiled Shot at Gabbard: ‘She’s the Favorite of the Russians’ to Run Third-Party
1 hour ago
Boris commented on honeygirl's video
1 hour ago
Boris favorited Diana's video
1 hour ago
Boris favorited James T. Kirk's video
1 hour ago

© 2019   Created by truth.   Powered by

Badges  |  Report an Issue  |  Terms of Service

content and site copyright 12160.info 2007-2019 - all rights reserved. unless otherwise noted